• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Fewer Major Bleeding Events with Bivalirudin For Patients with Acute Coronary Syndromes: The ACUITY study

  • in Cardiovascular
  • — 3 May, 2007
Fewer Major Bleeding Events with Bivalirudin For Patients with Acute Coronary Syndromes: The ACUITY study
AudioMedica News
Fewer Major Bleeding Events with Bivalirudin For Patients with Acute Coronary Syndromes: The ACUITY study
Fewer Major Bleeding Events with Bivalirudin For Patients with Acute Coronary Syndromes: The ACUITY study
00:00 /
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-285"/>
Harvey White

HARVEY WHITE, Auckland City Hospital, New Zealand

REFERENCE: ACUITY Trial, ACC.07 Scientific Session and i2 Innovations Summit. Presentation Number: 2414-5
Patients with acute coronary syndromes who take bivalirudin have fewer major bleeding events and a lower incidence of late stent thrombosis compared with those who receive standard heparin therapy. This is the finding of one year results from the ACUITY study announced by Gregg Stone of Columbia University, New York during the American College of Cardiology annual meeting that took place in New Orleans. Sarah Maxwell asked Harvey White at the Auckland City Hospital in New Zealand to comment about the ACUITY investigation.

[audio:https://www.audiomedica.com/podcasting/cardio/070502_harvey_white.mp3]

You may also like...

  • Endeavor: Alternative Drug-Eluting Stent? Endeavor: Alternative Drug-Eluting Stent? 12 Sep, 2005
  • Audio Journal of Cardiovascular Medicine: September 8th 2006 Audio Journal of Cardiovascular Medicine: September 8th 2006 8 Sep, 2006
  • Drug Eluting Stents: Higher Late Mortality in STEMI Patients Than Bare Metal: GRACE Registry Findings Drug Eluting Stents: Higher Late Mortality in STEMI Patients Than Bare Metal: GRACE Registry Findings 5 Sep, 2007
  • Fondaparinux: Better than Enoxaparin for Patients with Acute Coronary Syndromes? Fondaparinux: Better than Enoxaparin for Patients with Acute Coronary Syndromes? 12 Sep, 2005

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Audio Journal of Oncology in Advance – May 1st, 2007 – reporting from: American Association for Cancer Research 14-18 April, 2007 Los Angeles
  • Next story Can Road-Side Tranexamic Acid Therapy Reduce Mortality and Blood Transfusions after Trauma? The CRASH Trial.
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Microbiome Diversity Key To Survival After…
    • Childhood Obesity—Whose Business Is It?
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Oral Anticoagulant Edoxaban Alternative for…
  • Home
  • Cardiovascular
  • Fewer Major Bleeding Events with Bivalirudin For Patients with Acute Coronary Syndromes: The ACUITY study

© COPYRIGHT 2020 AUDIOMEDICA.COM.